Alpha Teknova, Inc. (TKNO) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Alpha Teknova, Inc. is a Delaware corporation operating as a non-accelerated filer, smaller reporting company, and emerging growth company. The company manufactures critical reagents for the life sciences market, including pre-poured media plates, liquid cell culture media, and molecular biology reagents. Operations are centralized at its headquarters in Hollister, California.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $10,454 | $9,576 | $30,536 | $28,480 |
| Gross Profit | $3,206 | $90 | $10,197 | $5,103 |
| Gross Margin | 30.7% | 0.9% | 33.4% | 17.9% |
| Net Loss | $(4,286) | $(7,565) | $(12,501) | $(21,026) |
| Operating Cash Flow (9M) | $(8,184) | $(11,455) | — | — |
| Cash & Short-term Investments | $22,116 | — | — | — |
| Long-term Debt (Net) | $13,076 | — | — | — |
Note: Q3 2024 gross margin was significantly depressed by $2.8 million in non-recurring inventory write-downs.
Material Changes vs. Prior Period
- Revenue Growth: Q3 2025 revenue increased 9.2% year-over-year (YoY), driven by a 16.0% increase in "Lab Essentials" revenue. "Clinical Solutions" revenue declined 13.1% YoY.
- Profitability Improvement: Net loss narrowed significantly to $4.3 million in Q3 2025 from $7.6 million in Q3 2024. Operating loss decreased 45.9% to $4.0 million.
- Margin Expansion: Gross margin improved to 30.7% in Q3 2025 from 0.9% in Q3 2024. Excluding the one-time inventory charges in the prior year, the adjusted gross margin improved from 29.8% to 30.7%.
- Expense Management: Total operating expenses decreased 4.0% YoY in Q3, with General and Administrative (G&A) expenses down 6.5% due to reduced spending on facilities, insurance, and professional fees.
- Debt Restructuring: In March 2025, the company entered a Second Amended and Restated Credit Agreement, refinancing its term loan and adding a $5.0 million revolver. This included capitalizing a $1.1 million exit fee.
Outlook, Risks, and Management Commentary
- Liquidity Position: As of September 30, 2025, the company held $3.2 million in cash and $18.9 million in short-term investments. The company maintains a minimum cash covenant of $8.0 million under its credit facility.
- Covenants: The credit agreement requires a minimum trailing twelve-month net revenue of $39.0 million for the period ending December 31, 2025. Current YTD revenue is $30.5 million.
- Capital Resources: The company filed a shelf registration statement (Form S-3) in July 2025, allowing for future securities offerings up to $225 million to fund operations or acquisitions.
- Risks: Key risks include the potential inability to achieve profitability, reliance on a limited number of suppliers, and exposure to macroeconomic factors such as inflation and interest rate fluctuations. The company also faces risks related to its status as an emerging growth company and potential dilution from future equity issuances.
- Legal: A former employee's wage and hour claim was settled in April 2025 for $0.4 million, which was accrued in the prior year.
Investor Verification Checklist
- Covenant Compliance: Verify if the company will meet the $39.0 million trailing twelve-month revenue covenant by December 31, 2025.
- Inventory Valuation: Review the $6.9 million inventory balance and the $1.7 million inventory reserve recorded in the first nine months of 2025 to assess obsolescence risks.
- Debt Service: Confirm the interest rate environment impact on the Term SOFR-based debt (currently ~6.45% margin + SOFR) and the $13.2 million principal balance.
- Customer Concentration: Note that "Distributor customer A" accounted for 24% of Q3 revenue and 20% of accounts receivable.
- Stock-Based Compensation: Monitor the $2.7 million stock-based compensation expense for the nine months ended September 2025 and the remaining unrecognized expense of $5.4 million related to options.